Short term efficacy and safety of patuzumab combined with trastuzumab in the treatment of HER-2 posi-tive breast cancer
Objective To analyze the short-term efficacy and safety of patuzumab combined with trastuzumab in the treatment of human epidermal growth factor receptor-2(HER-2)positive breast cancer.Methods A total of 104 HER-2 positive breast cancer patients admitted to the Department of Western Medicine of Nanyang Cancer Hospital from February 2023 to January 2024 were divided into the control group(52 cases)and the study group(52 cases)according to the random number table method.The control group received trastuzumab treatment,while the study group received pertuzumab combined with trastuzumab treatment,with a treatment period of 4 courses.Comparing the efficacy between the control group and the study group after 4 cours-es of treatment.Specifically,evaluated the levels of microRNA-375(miR-375),carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA),and carbohydrate antigen 125(CA125)before and after treatment.Additionally,assessed the scores for social function,cognitive function,physical function,and overall health.Furthermore,monitored the occurrence of liver function impairment,palpitations,gastrointestinal reactions,fatigue,cardiotoxici-ty,peripheral neurotoxicity,and bone marrow suppression during treatment.Results The objective remission rates of the control group and the study group after 4 treatment courses were 19.2％(10/52)and 36.5％(19/52),respectively.The study group had a higher rate than the control group(x2=3.873,P＜0.05).After treatment,com-pared with before treatment,the levels of miR-375,CA153,CEA,and CA125 in both groups of patients signifi-cantly decreased after treatment,and the levels in the study group were lower than those in the control group(t=9.760,2.764,11.147,5.402,P＜0.05).After treatment,compared with before treatment,the social function,cogni-tive function,physical function,and overall health scores of the two groups of patients were significantly increased,and the study group had higher scores than the control group(t=2.019,2.738,5.086,2.826,P＜0.05).There was no statistically significant difference in the incidence of liver function damage,palpitations,gastrointestinal reac-tions,fatigue,cardiac toxicity,peripheral neurotoxicity,and bone marrow suppression between the two groups(x2=0.000,0.088,0.231,0.205,P＞0.05).Conclusion The combination of patuzumab and trastuzumab in the treat-ment of HER-2 positive breast cancer patients can improve the clinical efficacy,reduce the level of tumor mark-ers,prevent disease progression,improve the quality of life of patients,and have good safety.
万方数据
维普
